Low Dose (2 mg) for Excessive Sweating

Phase 2

Waitlist Available

Research Sponsored by Atacama Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 6 (end of study)

Summary

This trial tests AT-5214 tablets on people with very sweaty palms to see if it can reduce their sweating. The study will compare two doses of the medication.

Eligible Conditions

Excessive Sweating
Sweaty palms

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 6 (end of study)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 6 (end of study)

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 6 (end of study) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

PHIS Reduction

Secondary study objectives

Absolute change in PHIS

Absolute change of Sweat Production

Change in Sweat Production

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Low Dose (2 mg)Experimental Treatment1 Intervention

Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).

Group II: High Dose (4 mg)Experimental Treatment1 Intervention

Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).

Group III: PlaceboPlacebo Group1 Intervention

Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dexmecamylamine

Not yet FDA approved

Do I qualify?Apply below to find out